Your genes. Your roadmap.™

MediMap®



Franziska Moeckel AVP, Personalized Health



Your genes. Your roadmap.™



Overview

Inova's Precision Medicine Journey


MediMap® Pharmacognomics at Inova

Implementation Considerations



What is Precision Medicine?





According to the Precision Medicine Initiative, precision medicine is...

...an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.

Your genes. Your roadmap.™



Overview

Inova's Precision Medicine Journey

MediMap® Pharmacognomics at Inova

Implementation Considerations



Start of Inova's Precision Medicine Journey



2010

Dr. John Niederhuber named ITMI CEO

2013

Epic (EMR) Launched

Women's Health Integrated Research Center Operational

\$50 million gift for Inova Dwight and Martha Schar Cancer Institute

Inova Women's Health Research Center's first biorepository in state of Virginia

2011

ITMI Launched

First ITMI Study: Premature Birth

2014

Inova Lab for Genomic Medicine Launched

First Clinical Pharmacogenomics (PGx) test

2016

Inova launches MediMap®, a pharmacogenomics test for newborns

Formation of Inova Molecular Tumor Board

Inova Heart and Vascular Institute opens clinical trials unit

Commonwealth of Virginia provides funding for Global Genomics and Bioinformatics Research Institute

NIH ECHO Grant Award (\$9.5 million)

2012

Trio Longitudinal Study

Congenital Anomalies Study

2015

Dr. Donald Trump named ICCRI CEO

Inova takes possession of ICPH Campus on October 1

"Hot Areas" in "Omics"*

*As identified by Dr. Eric Green, Director of the National Human Genome Research Institute (NHGRI)





Cancer Genomics



Somatic Tumor Profile

Targeted genomic sequence of tumor tissue; used in molecular tumor board (attended by patient's family)



Pharmacogenomics



Inova Genomics Laboratory

CAP- & CLIA-certified; >7 baseline & condition-spec PGx tests; MediMap® brand; >10,000 tests run since 2016



Ultra-Rare Genetic Disease Diagnostics



Congenital Disorders Study

NICU babies & adults; whole-genome-sequence (WGS); 60-70% successful diagnosis



Genomic Medicine 'Test Drive' Programs



MediMap® Baby

PGx test for newborns; 7 genes, 24 meds; at no additional charge; >97% have 1 or more actionable result



Prenatal & Newborn Genomic Analysis



First 1,000 Days of Life Study

WGS (family trios) & microbiome; genomic + survey + phenotypic data (from EHR)



Clinical Genomics Information Systems



Unique WGS Database

Over 134 birth countries; genomic + survey + phenotypic data (from EHR)

The Study of Omics



Genome	Epigenome	Transcriptome	Proteome	Metabolome	Microbiome
Factors affecting the DNA sequence	Factors affecting the rate at which genes are decoded into RNA	Factors affecting the RNA carrying decoded genes	Factors affecting protein assembly, folding, and reshaping	Factors affecting cell function	Understanding how our interactions with the microbes living inside us affect our health
TFbs TFbs	Gene Me Histone	MRNA Alternative splicing miRNA	Protein	Metabolites	Microbes
	Transcription	Expression	Translation	Function	

Phenome

Cumulative expression of disease-promoting or protective factors

- Autoimmune diseases
- Birth defects
- · Childhood weight gain
- Congenital disorders
- Developmental delay
- Drug metabolism
- Familial cancer
- Immunodeficiencies
- Longevity
- Metabolic syndrome
- Seizures
- Sporadic cancer


Ritchie MD, Holzinger ER, Li R, Pendergrass SA, Kim D. Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genet. 2015;16:85-97.

Pharmacogenomics (PGx) defined









Your genes. Your roadmap.™



Overview

Inova's Precision Medicine Journey

MediMap® Pharmacognomics at Inova

Implementation Considerations



Inova's PGx Journey



2014

Inova Lab for Genomic Medicine Launched

First Clinical Pharmacogenomics (PGx) test

2015

Expansion of singlegene-single-drug tests

Total of 11 tests live

Pilot deployment with physician champion

Inova funded; no reimbursement

Development of first panel test for newborns; 44 beta-tests



2016 MediMap®

First pharmacogenomic panel test for newborns launched with opening of new Women's & Children's hospital; 7 genes/25+ meds; >3,600 babies tested

Covered in worldwide "DNA Evolution" issue of NatGeo





Development of MediMap® brand umbrella for PGx testing at Inova

Launch of second MediMap panel for VIP360° Concierge Medicine / Corporate Health; >350 adults tested




2017

Creation of brand umbrella *Your genes. Your roadmap.*[™] for all genetic testing at Inova; >14,000 individuals tested

Launch of WGS offering - MyMap™

Inova Genomics Laboratory (IGL) receives CAP accreditation



Your genes. Your roadmap

Condition Specific



MediMap® ADHD

\$195



MediMap® Mind

PLUS \$395

MediMap® Plus



\$395 MediMap® Baby



Baseline Testing


\$295

MediMap® Basic

Inova.org/YourRoadmap




How it work?





How it work?



Physicians & Ordering Options for MediMap®




1

Inova Genomics
Laboratory physicians
place order in Epic



Patient appointment at IGL



MediMap® results are mailed to patient.

2

Inova physician places order in Epic



Patient appointment at IGL

Ordering physician will receive Epic notification to view PDF results.


MediMap® results are mailed to patient.

3

Physician writes MediMap® prescription



Patient appointment at IGL



MediMap® results are mailed to patient and ordering physisian

Epic & BPAs







PATIENT INFORMATION
NAME NEWTEST ASAP
MRN: 16100731
DOB: 8/28/1945
SEX: Male

PRECIMIEN DETAILS ORDERS


(CCESSION #: 17-322 BIZHAN

VPE: BUGGAL


OLLECTED: 7/31/2017

EFORTED: 8/10/2017





- Results populate EHR
- Reports to patients and physicians
- Expert "back-up"





PGx (Evidence Level) Review Bodies



Evidence Level 1	Actionable	ESTABLISHED EVIDENCE-BASED CLINICAL GUIDELINES	Recommendations extracted from evidence based guidelines issued by international pharmacogenetic consortia, professional societies or regulatory bodies (CPIC, DPWG, FDA, EMA, CPNDS, ACMG)*. Recommendations suitable for implementation in a clinical setting. Guidelines may be updated as new knowledge arises.
Evidence Level 2	Informative	REQUIRING FURTHER	There are no established evidence based guidelines issued by experts. The evidence documenting the genetic associations may be limited or insufficient. In some cases the evidence is still disputed. Recommendations are informative and implementation in a clinical setting is optional.











DPWG: Dutch Pharmacogenetics Working Group

U.S. Food and Drug Administration Protecting and Promoting Your Health



How it work?



What we provide





DISCOVER MORE ABOUT INOVA'S GENETIC TEST OFFERINGS








Patients & Individuals interested in MediMap®









Reporting





MEDIMAP® PLUS PHARMACOGENOMICS REPORT

DOB: 8/28/1945

SPECIMEN DETAILS COLLECTED: 7/31/2017

7/31/2017

Use With Caution

RECEIVED:

BIZHAN AARABI

Consider Alternatives

POTENTIALLY IMPACTED MEDICATIONS

Drug Class Standard Precautions

Category	Drug Class	Standard Frecautions
Anesthesia	Injectable Anesthetics	Propofol (Diprivan)
	Antifolates	Methotrexate (Trexall)
	Protein Kinase Inhibitors	Gefitinib (Iressa)
Anticancer Agents	Thiopurines	Azathioprine (Azasan, Imuran) Mercaptopurine (Purinethol, Purixan) Thioguanine (Tabloid)
	Angiotensin II Receptor Antagonists	Azilsartan (Edarbi, Edarbyclor) Candesartan (Atacand) Eprosartan (Teveten) Irbesartan (Avapro) Losartan (Cozaar, Hyzaar) Olmesartan (Benicar) Telmisartan (Micardis) Valsartan (Diovan, Entresto)
	Antianginal Agents	Ranolazine (Ranexa)
	Antiarrhythmics	Flecainide (Tambocor) Mexiletine (Mexitil) Propafenone (Rythmol)
	Anticoagulants	Apixaban (Eliquis) Dabigatran Etexilate (Pradaxa) Edoxaban (Savaysa) Fondaparinux (Arixtra) Rivaroxaban (Xarelto) Warfarin (Coumadin)
Cardiovascular	Antiplatelets	Clopidogrel (Plavix) Prasugrel (Effient) Ticagrelor (Brilinta) Vorapaxar (Zontivity)

RED CATEGORY (STOP)

- · Medications in this category may not work well or may cause unwanted side effects.
- . If a person is prescribed one of these medications, then a change in dose with close monitoring may be recommended.
- . In some cases, a change in medication may be strongly recommended.


1 YELLOW CATEGORY (USE CAUTION)

- · These medications also may not work as well or cause unwanted side effects.
- . If a person is prescribed one of these medications, then a change in dose with some extra monitoring may be recommended.
- · A change in medication may not be needed.

√ GREEN CATEGORY (GO)


- · Based on the test results, these medications should work as expected
- · They may be prescribed as usual.

Patient Information Card: A wallet-sized patient information card is located on the last page of the MediMap™ VIP 360° report. This card is a summary genetic report for you to share with your healthcare providers (at Inova or elsewhere) including pharmacists. The purpose of this card is also to allow your PGx results to be reinterpreted in the future. We recommend sharing the full report with other healthcare providers.





Your genes. Your roadmap



Based on that genetic profile, it listed medications that might cause unwanted side effects like the ones he was experiencing.

"Lo and behold, the statins are bloody dangerous for me,"

"They just do a mouth swab and 4 to 6 weeks later you get this pretty little report back."

-Hodson said.

"As soon as we heard about MediMap, we knew right away we wanted to do this. The testing is innovative and cutting-edge, exactly what Inova aims to be."

"What appealed to me was that we would know what medications would be compatible with her system later, and if they're not, we don't even have to try them — we can go to the ones we know work for her,"

-Calla's mom, Sarah Johnson, an obstetrics nurse at Inova and Clinical Director of Family Centered Care.



Dizzy Poe We got to have the testing done on our baby after she was born in January. We just got the results back last month. I am hoping that soon we can have our other children tested. The information is so helpful to know.

Like · Reply · Message · Yesterday at 12:22am

20

Tasha Minor Hall My baby is a medimap baby

Like · Reply · Message · 🙆 1 · August 23 at 5:25pm





Like · Reply · Message · August 12 at 1:46pm

Black Box Warnings





<u>Description</u> Catalyst for many reactions involved in drug metabolism & controls the metabolism of over 70% of prescribed drugs. CYP2C19 helps metabolize xenobiotics (Mephenytoin, Diazepam, & Barbiturates) & several groups of drugs (Proton Pump Inhibitors & Antiepileptic's) in the body. Patients' with reduced CYP2C19 are poor metabolizers for Plavix, hence they may remain at risk for heart cardiovascular death. 2% - 14% of the U.S. population has reduced CYP2C19 enzymes. If variant present, patient should receive alternative medication.

WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS See full prescribing information for complete boxed warning.


- Effectiveness of Plavix depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19.
- Poor metabolizers treated with Plavix at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function.
- Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy.
- Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.



YouTube

Search

Q



Your genes. Your roadmap.™



Overview

Inova's Precision Medicine Journey

MediMap® Pharmacognomics at Inova

Implementation Considerations






How it work?





How it work?



The Genetic Information Nondiscrimination Act of 2008 (Approved May 21, 2008)



To prohibit discrimination on the basis of genetic information with respect to <u>health</u> <u>insurance</u> and <u>employment</u>.

*Note: Currently excludes life insurance, disability insurance, and long-term care insurance.




Factors to consider for Inova:

- Inova is a health system / provider...
- ...rendering services to patients who are also employed by Inova.
- Inova is a self-insured employer...
- ...offering health plan choices to its employees and their dependents (incl. access to a wellness program).
- Inova has an in-house CAP-accredited and CLIA-certified genomics laboratory (IGL)...
- ...providing genetic testing services to patients (who could also be Inova employees).

Genomic Data Safety





PGx → MediMap® → Your genes. Your roadmap.™



MediMap® Newborn was conceived in late 2015, born in January 2016, and received siblings in 2017.



Your genes. Your roadmap.



MyMap[™]

Whole Genome Sequencing







Overview

Inova's Precision Medicine Journey

MediMap® Pharmacognomics at Inova

Implementation Considerations



How to get MediMap





Interested to learn more about MediMap® testing?

Would like to schedule an appointment? (doctor's referral not required)

We want to hear from you!



MediMap@inova.org

703.776.8200

inova.org/MediMap

32